SPY: price today and chart

The IMF warned that government bond yields could spike in a disorderly way as rising inflation, mounting debt and AI-related borrowing pressure sovereign bond markets. Yields in several advanced economies have reached multidecade highs, driven partly by higher energy costs from the Middle East conflict, and global public debt is near its highest level since World War II. Hyperscalers’ share of global investment-grade bond issuance has risen to 10% from less than 1% since 2024, while hedge funds’ share of U.S. Treasuries rose to about 9% in 2025 from about 4% in 2022, which the IMF says leaves the market susceptible to a disorderly unwind. The fund also flagged “circular” AI financing: 14 disclosed deals since 2023 channeled about $300 billion of equity and $650 billion of debt, in exchange for $1.4 trillion of future revenue commitments.

Michael Burry warned that stocks at new highs could be a “bull trap,” but is holding back on adding shorts; about 10% of his portfolio is in puts, with most of the rest in longs and LEAPS. He has moved his Fannie Mae and Freddie Mac common shares into junior preferred stock, betting that a government resolution of Treasury’s roughly $388 billion senior preferred liquidation preference could lift returns four to five times from current levels. He expects a favorable resolution within two years, though he said the delay made him “antsy” given a deteriorating multifamily housing situation. FNMA and FMCC have fallen for seven straight weeks, down 68% and 69% year-to-date, respectively.

Illumina (ILMN) shares have returned 118% over six months and more than 100% year to date, versus 14% for the S&P 500 ETF, as its core sequencing business shows signs of recovery. Clinical markets make up about 65% of sequencing consumables revenue and grew 15% outside China in Q2, while research demand remains cautious and is expected to decline in 2026. Q2 revenue rose 9.5% to $1.16 billion with a 22.5% non-GAAP operating margin, and management raised its 2026 revenue outlook to $4.60–$4.64 billion and adjusted EPS guidance to $5.30–$5.40. More than 95 NovaSeq X instruments were placed in Q2, and since customers take six to nine months to reach normal consumables usage, these could support revenue into 2027, while multi-omics and the Billion Cell Atlas are still early. At 46.17x trailing and 40.32x forward earnings, the article argues much of the recovery already appears reflected in the share price, with risks from research funding, China, and higher freight and memory costs.

Asian technology stocks fell on Tuesday as a U.S. chip sell-off spread to regional markets, with worries over AI financing and rising competition weighing on sentiment. South Korea's SK Hynix dropped more than 8% and Samsung Electronics fell 7.9%, both hitting their lowest intraday levels since August, while Japan's SoftBank Group sank 8.03%. Other Japanese chip and equipment stocks also declined after the Nasdaq Composite fell 0.44% on Monday. Micron Technology slid 3.9% as investors weighed competition from China's ChangXin Memory Technologies (CXMT), which reported progress on a new chip structure that boosts memory density. Analysts quoted in the article said the sell-off reflected broader anxiety over the AI trade rather than a fundamental shift, since CXMT has yet to reach large-scale production and still lags in HBM, while the Intel and Broadcom CEOs warned that access to capital could become a headwind for the AI boom.

TransDigm Group (NYSE:TDG) closed at $1,107.99 on October 9 and returned -10.15% over six months, versus 24.3% for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. The negative book value of about -$167.97 per share is a deliberate result of borrowing to fund buybacks and large special dividends, which pushed debt to $33.49 billion, and the company pays no regular dividend. Its proprietary aircraft components generate high aftermarket margins, with a 46.01% operating margin and 22.50% revenue growth in the latest quarter, and a current ratio above three means no immediate liquidity problem. The main risk is the installed base, since aftermarket demand depends on aircraft flying and retiring slowly, and a sustained fall in flight hours would hit the highest-margin revenue first. The article concludes that borrowing built this structure and is the factor most likely to unbuild it.

Ventas (NYSE: VTR) closed at $82.04 on October 9 and has returned -2.8% over six months, trailing the 24.3% gain of the Insider Monkey Billionaire Index and the 15.1% gain of the SPDR S&P 500 ETF Trust. The article argues that the payout ratio above 370% is a distortion caused by large real estate depreciation, which is deducted before earnings, while free cash flow of about a billion dollars actually funds the dividend. Revenue grew 21.70% in the latest quarter, helped by senior housing occupancy that is still recovering. However, coverage is thin: the current ratio is 0.30 against $12.92 billion of debt, and ROE of 2.01% sits below ROA of 2.17%. The author says senior housing occupancy is the key swing factor in both directions.

Charter Communications (NASDAQ: CHTR) closed at $103.38 on October 9 and has returned -54.3% over the last six months, compared with 24.3% for the Insider Monkey Billionaire Index and 15.1% for the SPDR S&P 500 ETF Trust. One group views Charter as a near-monopoly cable infrastructure business with a 23.50% operating margin and operating cash flow more than three times reported profit, arguing that a multiple below three times earnings looks too cheap. The other sees a highly indebted borrower losing broadband customers to fibre and fixed wireless, and 41.52% of the float is sold short. The article argues that trailing earnings reflect deal accounting from the $34.5 billion Cox Communications acquisition and the Liberty Broadband transaction, and that revenue fell 1.70% in the latest quarter. It also cites debt of $96.71 billion against about half a billion dollars in cash and a current ratio of 0.36.

ServiceNow grew revenue 24% but earnings fell 22.60%, as the company deliberately spent on sales headcount and engineering payroll to win future customers. The article argues the company did not cut prices to win deals, since gross margin stays at 74.77%, and free cash flow came in at nearly three times reported net income. The stock closed at $140.86 on October 9 and has returned 58.1% over six months, outpacing the Insider Monkey Billionaire Index's 24.3% and the State Street SPDR S&P 500 ETF Trust's 15.1%. According to the piece, the main risk is valuation: the stock trades at 28.14 times forward earnings, well below its trailing multiple, and a current ratio of 0.70 leaves little room for a bad year. The earnings recovery depends on spending stopping and growth holding up.